Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

  • Revenue in USD (TTM)43.29bn
  • Net income in USD6.83bn
  • Incorporated1994
  • Employees95.44k
  • Location
    Sanofi SA54 rue la BoetiePARIS 75008FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
announced
Transaction
value
Amunix Pharmaceuticals IncDeal completed21 Dec 202121 Dec 2021Deal completed-6.02%1.25bn
American Finance Trust Inc-Office Building(3)Deal completed20 Dec 202120 Dec 2021Deal completed-6.01%261.00m
ORIGIMM Biotechnology GmbHAnnounced01 Dec 202101 Dec 2021Announced-2.61%--
Kadmon Holdings IncDeal completed08 Sep 202108 Sep 2021Deal completed-6.07%1.76bn
Data delayed at least 15 minutes, as of Aug 17 2022 16:38 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Moderna Inc23.00bn14.06bn66.95bn2.70k5.313.804.752.9632.8032.8053.7945.881.093.189.768,516,667.0066.6241.17105.9066.7882.29--61.1252.351.71--0.04070.002,199.12179.441,733.33--53.67--
Regeneron Pharmaceuticals Inc14.23bn5.69bn67.82bn10.37k12.813.4011.694.9250.0750.07125.24188.930.58441.022.341,372,184.0023.3625.6427.1329.9984.9788.5139.9739.114.3911.870.1155--89.1427.02129.8655.241.52--
Vertex Pharmaceuticals Incorporated8.35bn3.19bn76.64bn3.90k23.926.3522.769.0812.3712.3732.3346.610.60072.887.382,141,135.0022.9818.0127.2921.8788.1387.7738.2629.174.3628.000.03890.0022.0634.79-13.63--32.96--
Gilead Sciences, Inc.27.52bn4.14bn77.71bn14.40k19.253.9112.732.883.283.2821.8116.140.42064.116.661,910,764.006.288.357.3710.0275.5979.5614.9322.221.276.690.564658.7610.60-2.124,960.98-14.34-4.999.07
Zoetis Inc8.00bn2.09bn79.37bn12.10k39.5017.8132.0010.194.414.4116.859.770.57441.186.50660,743.8015.0013.7918.4016.0470.4468.7526.1223.941.4611.640.589422.5316.499.7324.3619.9317.1720.72
Sanofi SA (ADR)43.29bn6.83bn123.38bn95.44k16.651.5513.172.622.712.7117.2529.180.35911.385.73453,546.805.685.196.916.2369.4568.0615.8215.360.86132.430.2311--4.832.46-49.387.20-0.387--
Amgen, Inc.26.38bn6.58bn132.86bn24.20k21.3655.7413.565.1111.8011.8047.504.520.44321.485.381,090,248.0011.0511.0714.3213.4075.7579.2924.9230.881.177.460.937949.282.182.47-18.87-5.261.0111.97
Bristol-Myers Squibb Co47.14bn6.62bn160.06bn32.20k24.884.909.343.393.013.0121.4915.270.44654.586.001,464,099.006.292.677.763.2979.2274.1814.086.541.345.550.5629163.849.0919.01177.589.43-4.355.22
Data as of Aug 17 2022. Currency figures normalised to Sanofi SA's reporting currency: US Dollar USD

Institutional shareholders

6.10%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 30 Jun 202277.00m3.04%
Fisher Asset Management LLCas of 30 Jun 202217.61m0.70%
Boston Partners Global Investors, Inc.as of 30 Jun 202211.90m0.47%
Fidelity Management & Research Co. LLCas of 30 Jun 202210.13m0.40%
Managed Account Advisors LLCas of 30 Jun 20229.46m0.37%
BlackRock Investment Management LLCas of 30 Jun 20227.19m0.28%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20226.56m0.26%
Strategic Advisers LLCas of 30 Jun 20226.36m0.25%
Invesco Advisers, Inc.as of 31 Mar 20224.32m0.17%
Camber Capital Management LPas of 31 Mar 20224.00m0.16%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.